William F. C. Rigby

Dartmouth Institute for Health Policy and Clinical Practice — United States

Medicine · Health Sciences

42h-index6.5kcitations125works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(50), Chronic Lymphocytic Leukemia Research(25), Autoimmune and Inflammatory Disorders Research(22), Systemic Lupus Erythematosus Research(18), RNA Research and Splicing(15)

Publications125 total

Immune checkpoint VISTA protects the skin from injury by ultraviolet light by regulating the STING-mediated (IFN-I) response 2793
The Journal of Immunology·2025Open Access
POS1394 CO-STIMULATORY BLOCKADE CAUSES TARGETED QUANTITATIVE CONTRACTIONS IN EXTRAFOLLICULAR B-CELL SUBSETS WITH CLINICAL IMPROVEMENT IN SEROPOSITIVE RA
Annals of the Rheumatic Diseases·2025Open Access
Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study
RMD Open·2025· 3 citedOpen Access
POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
2023· 1 citedOpen Access
The thematic role of extracellular loop of VraG in activation of the membrane sensor GraS in a cystic fibrosis MRSA strain differs in nuance from the CA-MRSA strain JE2
PLoS ONE·2022· 4 citedOpen Access
Regulation of neutrophil myeloperoxidase inhibitor <scp>SPIN</scp> by the small <scp>RNA</scp> Teg49 in <i>Staphylococcus aureus</i>
Molecular Microbiology·2022· 2 citedOpen Access
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Rheumatology and Therapy·2021· 6 citedOpen Access
Journal Club: Efficacy of Tocilizumab in Early Systemic Sclerosis–Related Interstitial Lung Disease
ACR Open Rheumatology·2021· 2 citedOpen Access
HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA
Arthritis Research & Therapy·2021· 49 citedOpen Access
Differential Enhancement of Neutrophil Phagocytosis by Anti–Bactericidal/Permeability-Increasing Protein Antibodies
The Journal of Immunology·2021· 4 citedOpen Access
Bactericidal/Permeability-Increasing Protein Preeminently Mediates Clearance of Pseudomonas aeruginosa In Vivo via CD18-Dependent Phagocytosis
Frontiers in Immunology·2021· 16 citedOpen Access
The extracellular loop of the membrane permease VraG interacts with GraS to sense cationic antimicrobial peptides in Staphylococcus aureus
PLoS Pathogens·2021· 26 citedOpen Access
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program
Drug Safety·2021· 40 citedOpen Access
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
Annals of the Rheumatic Diseases·2021· 135 citedOpen Access
Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions
Journal of Translational Autoimmunity·2021· 31 citedOpen Access
Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia
Infection and Immunity·2020· 3 citedOpen Access
Recurrent rheumatoid arthritis following allogeneic bone marrow transplant and seronegativity induced by rituximab therapy
Seminars in Arthritis and Rheumatism·2020· 1 cited
THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
Annals of the Rheumatic Diseases·2020
THU0160 THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NAÏVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED ‘EARLY AMPLE’ TRIAL
Annals of the Rheumatic Diseases·2020
FRI0115 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, AND HEALTH-RELATED QUALITY OF LIFE, AND REDUCED FATIGUE OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE-NAÏVE: RESULTS FROM THE FINCH 3 STUDY
Annals of the Rheumatic Diseases·2020· 3 cited
page 1 of 7Next →

Frequent Co-authors

B. JoNell Hamilton(9), Andrea Rubbert‐Roth(5), Ronald van Vollenhoven(5), Gerd R Burmester(5), Jonathan D. G. Jones(5), John E. Connolly(4), Eszter Nagy(3), Stanley Cohen(3), Paul P. Tak(3), William Stohl(3), Jonathan Kay(3), Sophie Dimonaco(3), Ralph C. Nichols(3), Seth A. Brooks(3), Patricia A. Pioli(3), Sladjana Skopelja‐Gardner(3), Valderílio Feijó Azevedo(2), Ricardo Blanco(2), Cunshan Wang(2), Sujatha Menon(2)